Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human
placental adherent stromal cells for commercial use in disease treatment. According to the company's website,
it extracts adult stem cells exclusively from postnatal placentas.
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human
placental adherent stromal cells for commercial use in disease treatment. According to the company's website,
it extracts adult stem cells exclusively from postnatal placentas.